Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128082 · ClinicalTrials.gov registry record · Phase 2
The Long COVID Treatment Trial
A Phase 2 study of Long COVID, sponsored by Scripps Translational Science Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT07128082 is a Phase 2 study of Long COVID that is active but no longer recruiting, run by Scripps Translational Science Institute. The registered enrollment target is 1,000 participants, below the 2,168-participant average among 50 other Long COVID trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07128082, a Phase 2 study of Long COVID, is active but no longer recruiting, sponsored by Scripps Translational Science Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (1)
California
- Scripps Research - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07128082
The ClinicalTrials.gov registry entry for NCT07128082 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,168-participant average among 50 other Long COVID trials with a reported enrollment target (54% lower). The listed sponsor is Scripps Translational Science Institute, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07128082 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07128082 about?
NCT07128082 is a clinical study titled "The Long COVID Treatment Trial". The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that h...
What is the current status of trial NCT07128082?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,000 participants. The study started on 2025-10-30. Estimated completion is 2026-12.
What conditions does trial NCT07128082 study?
This clinical trial studies the following conditions: Long COVID.
What interventions are being tested in trial NCT07128082?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT07128082?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128082 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NE3107 in Adults With Neurological Symptoms of Long COVID
RECRUITING · Phase 2
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
RECRUITING · Phase 2
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
LIFT: Life Improvement Trial
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.